Treatment of Recurrent Perforating Intestinal Ulcers with Thalidomide in Behcet's Disease

OBJECTIVE To report the beneficial effects of thalidomide on recurrent perforating intestinal ulcers in a patient with Behçet's disease (BD). CASE SUMMARY A 24-year-old Turkish woman with BD was admitted to our hospital because of severe abdominal pain and vomiting. She had been receiving colch...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Annals of pharmacotherapy 2004-05, Vol.38 (5), p.808-811
Hauptverfasser: Sayarlioglu, Mehmet, Kotan, Mehmet Cetin, Topcu, Nazan, Bayram, Irfan, Arslanturk, Hasan, Gul, Ahmet
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 811
container_issue 5
container_start_page 808
container_title The Annals of pharmacotherapy
container_volume 38
creator Sayarlioglu, Mehmet
Kotan, Mehmet Cetin
Topcu, Nazan
Bayram, Irfan
Arslanturk, Hasan
Gul, Ahmet
description OBJECTIVE To report the beneficial effects of thalidomide on recurrent perforating intestinal ulcers in a patient with Behçet's disease (BD). CASE SUMMARY A 24-year-old Turkish woman with BD was admitted to our hospital because of severe abdominal pain and vomiting. She had been receiving colchicine 1.5 mg/day and azathioprine 150 mg/day for treatment of BD for 2 years. During emergency laparatomy, 2 perforating ulcers were detected in the anterior cecum, which were treated with debridement and primary repair. She experienced 2 more episodes of intestinal perforations during the second and fifth weeks despite intense immunosuppressive treatment with methylprednisolone and cyclophosphamide. New intestinal perforations were found in the posterolateral cecum and transverse colon during the second operation and in the terminal ileum during the third one. Thalidomide 100 mg/day was then started, and the symptoms disappeared within 2 weeks. The woman experienced no other intestinal perforation during the follow-up period of 4 months. DISCUSSION The mode of action of thalidomide in BD is still unclear. In BD, various cytokines have been shown to be abnormally expressed and neutrophils are overactive. This is a possible mechanism of action with thalidomide reducing both tumor necrosis factor and the neutrophil migration. CONCLUSIONS Thalidomide may be an effective alternative treatment for BD patients with recurrent and perforating intestinal ulcers despite intense immunosuppressive therapy.
doi_str_mv 10.1345/aph.1D524
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71838851</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1345_aph.1D524</sage_id><sourcerecordid>71838851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c367t-af075e40c550b054348a4d13d5389b3a98588e68b4779f8a59f34a0c99d348443</originalsourceid><addsrcrecordid>eNptkMtOwzAQRS0E4lFY8APIG0AsUsax3ThLaHlJSCBUFqwsN5k0RnkUO1HE3-PSSmxYzR3p6M7oEHLKYMy4kNdmVY7ZTMZihxwyKeJoEiewGzJMIIJYwQE58v4TAFIWp_vkgElgIGN-SD7mDk1XY9PRtqBvmPXOrZdXdEXrTGebJX1qOvQhmYq-Vxk6TwfblXRemsrmbW1zpLaht1hm2F16OrMejcdjsleYyuPJdo7I-_3dfPoYPb88PE1vnqOMT5IuMgUkEgVkUsICpOBCGZEznkuu0gU3qZJK4UQtRJKkhTIyLbgwkKVpHlAh-IhcbHpXrv3qw6O6tj7DqjINtr3XCVNcKckCeLUBM9d677DQK2dr4741A732qINH_esxsGfb0n5RY_5HbsX9XfVmifqz7V3Q4_9tOt-ApV2Wg3WofW2qKvQyPQwDV1pqBYr_AJephoo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71838851</pqid></control><display><type>article</type><title>Treatment of Recurrent Perforating Intestinal Ulcers with Thalidomide in Behcet's Disease</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Sayarlioglu, Mehmet ; Kotan, Mehmet Cetin ; Topcu, Nazan ; Bayram, Irfan ; Arslanturk, Hasan ; Gul, Ahmet</creator><creatorcontrib>Sayarlioglu, Mehmet ; Kotan, Mehmet Cetin ; Topcu, Nazan ; Bayram, Irfan ; Arslanturk, Hasan ; Gul, Ahmet</creatorcontrib><description>OBJECTIVE To report the beneficial effects of thalidomide on recurrent perforating intestinal ulcers in a patient with Behçet's disease (BD). CASE SUMMARY A 24-year-old Turkish woman with BD was admitted to our hospital because of severe abdominal pain and vomiting. She had been receiving colchicine 1.5 mg/day and azathioprine 150 mg/day for treatment of BD for 2 years. During emergency laparatomy, 2 perforating ulcers were detected in the anterior cecum, which were treated with debridement and primary repair. She experienced 2 more episodes of intestinal perforations during the second and fifth weeks despite intense immunosuppressive treatment with methylprednisolone and cyclophosphamide. New intestinal perforations were found in the posterolateral cecum and transverse colon during the second operation and in the terminal ileum during the third one. Thalidomide 100 mg/day was then started, and the symptoms disappeared within 2 weeks. The woman experienced no other intestinal perforation during the follow-up period of 4 months. DISCUSSION The mode of action of thalidomide in BD is still unclear. In BD, various cytokines have been shown to be abnormally expressed and neutrophils are overactive. This is a possible mechanism of action with thalidomide reducing both tumor necrosis factor and the neutrophil migration. CONCLUSIONS Thalidomide may be an effective alternative treatment for BD patients with recurrent and perforating intestinal ulcers despite intense immunosuppressive therapy.</description><identifier>ISSN: 1060-0280</identifier><identifier>EISSN: 1542-6270</identifier><identifier>DOI: 10.1345/aph.1D524</identifier><identifier>PMID: 15010523</identifier><language>eng</language><publisher>Los Angeles, CA: Harvey Whitney Books</publisher><subject>Adjuvants, Immunologic - therapeutic use ; Adult ; Behcet Syndrome - drug therapy ; Female ; Humans ; Intestinal Perforation - drug therapy ; Recurrence ; Thalidomide - therapeutic use</subject><ispartof>The Annals of pharmacotherapy, 2004-05, Vol.38 (5), p.808-811</ispartof><rights>2004 SAGE Publications</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c367t-af075e40c550b054348a4d13d5389b3a98588e68b4779f8a59f34a0c99d348443</citedby><cites>FETCH-LOGICAL-c367t-af075e40c550b054348a4d13d5389b3a98588e68b4779f8a59f34a0c99d348443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1345/aph.1D524$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1345/aph.1D524$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15010523$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sayarlioglu, Mehmet</creatorcontrib><creatorcontrib>Kotan, Mehmet Cetin</creatorcontrib><creatorcontrib>Topcu, Nazan</creatorcontrib><creatorcontrib>Bayram, Irfan</creatorcontrib><creatorcontrib>Arslanturk, Hasan</creatorcontrib><creatorcontrib>Gul, Ahmet</creatorcontrib><title>Treatment of Recurrent Perforating Intestinal Ulcers with Thalidomide in Behcet's Disease</title><title>The Annals of pharmacotherapy</title><addtitle>Ann Pharmacother</addtitle><description>OBJECTIVE To report the beneficial effects of thalidomide on recurrent perforating intestinal ulcers in a patient with Behçet's disease (BD). CASE SUMMARY A 24-year-old Turkish woman with BD was admitted to our hospital because of severe abdominal pain and vomiting. She had been receiving colchicine 1.5 mg/day and azathioprine 150 mg/day for treatment of BD for 2 years. During emergency laparatomy, 2 perforating ulcers were detected in the anterior cecum, which were treated with debridement and primary repair. She experienced 2 more episodes of intestinal perforations during the second and fifth weeks despite intense immunosuppressive treatment with methylprednisolone and cyclophosphamide. New intestinal perforations were found in the posterolateral cecum and transverse colon during the second operation and in the terminal ileum during the third one. Thalidomide 100 mg/day was then started, and the symptoms disappeared within 2 weeks. The woman experienced no other intestinal perforation during the follow-up period of 4 months. DISCUSSION The mode of action of thalidomide in BD is still unclear. In BD, various cytokines have been shown to be abnormally expressed and neutrophils are overactive. This is a possible mechanism of action with thalidomide reducing both tumor necrosis factor and the neutrophil migration. CONCLUSIONS Thalidomide may be an effective alternative treatment for BD patients with recurrent and perforating intestinal ulcers despite intense immunosuppressive therapy.</description><subject>Adjuvants, Immunologic - therapeutic use</subject><subject>Adult</subject><subject>Behcet Syndrome - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Intestinal Perforation - drug therapy</subject><subject>Recurrence</subject><subject>Thalidomide - therapeutic use</subject><issn>1060-0280</issn><issn>1542-6270</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkMtOwzAQRS0E4lFY8APIG0AsUsax3ThLaHlJSCBUFqwsN5k0RnkUO1HE3-PSSmxYzR3p6M7oEHLKYMy4kNdmVY7ZTMZihxwyKeJoEiewGzJMIIJYwQE58v4TAFIWp_vkgElgIGN-SD7mDk1XY9PRtqBvmPXOrZdXdEXrTGebJX1qOvQhmYq-Vxk6TwfblXRemsrmbW1zpLaht1hm2F16OrMejcdjsleYyuPJdo7I-_3dfPoYPb88PE1vnqOMT5IuMgUkEgVkUsICpOBCGZEznkuu0gU3qZJK4UQtRJKkhTIyLbgwkKVpHlAh-IhcbHpXrv3qw6O6tj7DqjINtr3XCVNcKckCeLUBM9d677DQK2dr4741A732qINH_esxsGfb0n5RY_5HbsX9XfVmifqz7V3Q4_9tOt-ApV2Wg3WofW2qKvQyPQwDV1pqBYr_AJephoo</recordid><startdate>20040501</startdate><enddate>20040501</enddate><creator>Sayarlioglu, Mehmet</creator><creator>Kotan, Mehmet Cetin</creator><creator>Topcu, Nazan</creator><creator>Bayram, Irfan</creator><creator>Arslanturk, Hasan</creator><creator>Gul, Ahmet</creator><general>Harvey Whitney Books</general><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040501</creationdate><title>Treatment of Recurrent Perforating Intestinal Ulcers with Thalidomide in Behcet's Disease</title><author>Sayarlioglu, Mehmet ; Kotan, Mehmet Cetin ; Topcu, Nazan ; Bayram, Irfan ; Arslanturk, Hasan ; Gul, Ahmet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c367t-af075e40c550b054348a4d13d5389b3a98588e68b4779f8a59f34a0c99d348443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adjuvants, Immunologic - therapeutic use</topic><topic>Adult</topic><topic>Behcet Syndrome - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Intestinal Perforation - drug therapy</topic><topic>Recurrence</topic><topic>Thalidomide - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sayarlioglu, Mehmet</creatorcontrib><creatorcontrib>Kotan, Mehmet Cetin</creatorcontrib><creatorcontrib>Topcu, Nazan</creatorcontrib><creatorcontrib>Bayram, Irfan</creatorcontrib><creatorcontrib>Arslanturk, Hasan</creatorcontrib><creatorcontrib>Gul, Ahmet</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Annals of pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sayarlioglu, Mehmet</au><au>Kotan, Mehmet Cetin</au><au>Topcu, Nazan</au><au>Bayram, Irfan</au><au>Arslanturk, Hasan</au><au>Gul, Ahmet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Recurrent Perforating Intestinal Ulcers with Thalidomide in Behcet's Disease</atitle><jtitle>The Annals of pharmacotherapy</jtitle><addtitle>Ann Pharmacother</addtitle><date>2004-05-01</date><risdate>2004</risdate><volume>38</volume><issue>5</issue><spage>808</spage><epage>811</epage><pages>808-811</pages><issn>1060-0280</issn><eissn>1542-6270</eissn><abstract>OBJECTIVE To report the beneficial effects of thalidomide on recurrent perforating intestinal ulcers in a patient with Behçet's disease (BD). CASE SUMMARY A 24-year-old Turkish woman with BD was admitted to our hospital because of severe abdominal pain and vomiting. She had been receiving colchicine 1.5 mg/day and azathioprine 150 mg/day for treatment of BD for 2 years. During emergency laparatomy, 2 perforating ulcers were detected in the anterior cecum, which were treated with debridement and primary repair. She experienced 2 more episodes of intestinal perforations during the second and fifth weeks despite intense immunosuppressive treatment with methylprednisolone and cyclophosphamide. New intestinal perforations were found in the posterolateral cecum and transverse colon during the second operation and in the terminal ileum during the third one. Thalidomide 100 mg/day was then started, and the symptoms disappeared within 2 weeks. The woman experienced no other intestinal perforation during the follow-up period of 4 months. DISCUSSION The mode of action of thalidomide in BD is still unclear. In BD, various cytokines have been shown to be abnormally expressed and neutrophils are overactive. This is a possible mechanism of action with thalidomide reducing both tumor necrosis factor and the neutrophil migration. CONCLUSIONS Thalidomide may be an effective alternative treatment for BD patients with recurrent and perforating intestinal ulcers despite intense immunosuppressive therapy.</abstract><cop>Los Angeles, CA</cop><pub>Harvey Whitney Books</pub><pmid>15010523</pmid><doi>10.1345/aph.1D524</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1060-0280
ispartof The Annals of pharmacotherapy, 2004-05, Vol.38 (5), p.808-811
issn 1060-0280
1542-6270
language eng
recordid cdi_proquest_miscellaneous_71838851
source MEDLINE; SAGE Complete
subjects Adjuvants, Immunologic - therapeutic use
Adult
Behcet Syndrome - drug therapy
Female
Humans
Intestinal Perforation - drug therapy
Recurrence
Thalidomide - therapeutic use
title Treatment of Recurrent Perforating Intestinal Ulcers with Thalidomide in Behcet's Disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T16%3A45%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Recurrent%20Perforating%20Intestinal%20Ulcers%20with%20Thalidomide%20in%20Behcet's%20Disease&rft.jtitle=The%20Annals%20of%20pharmacotherapy&rft.au=Sayarlioglu,%20Mehmet&rft.date=2004-05-01&rft.volume=38&rft.issue=5&rft.spage=808&rft.epage=811&rft.pages=808-811&rft.issn=1060-0280&rft.eissn=1542-6270&rft_id=info:doi/10.1345/aph.1D524&rft_dat=%3Cproquest_cross%3E71838851%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71838851&rft_id=info:pmid/15010523&rft_sage_id=10.1345_aph.1D524&rfr_iscdi=true